RxDoctor Payments Data

Julia Fuster, PA

Medical · Farmington, ARNPI 1083190318

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 44.9% of the total. 2025 is the largest year on record at $523, 3.3 times the $159 reported in 2022.

$884in general payments, 2019–2025

Across 34 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$397
  • AstraZeneca$216
  • Boehringer Ingelheim$88
  • Novo Nordisk$59
  • Viatris Specialty LLC$38
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$884 in reported general payments places this provider in the 55th percentile of 133 medical providers in Arkansas.

See all medical providers in Arkansas

Medicare billing

Part B allowed, 2024
$12,626
Medicare patients
89
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin18$10,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,489
PaxlovidNirmatrelvir/Ritonavir12$2,858
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$1,149
Gabapentin44$437
Albuterol Sulfate HfaAlbuterol Sulfate14$330
Rosuvastatin Calcium21$253
Clotrimazole12$253
Duloxetine Hcl20$241
Cephalexin35$219
Atorvastatin Calcium38$218
Levothyroxine Sodium32$200
Lisinopril28$198
Cefdinir14$176
Omeprazole19$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$88$10,46818 claims
PfizerPaxlovid$22$2,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 133 medical providers in Arkansas.

Other medical in Farmington

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →